Eli Lilly's foray into telehealth shows the emerging importance virtual care platforms are playing in the rising popularity ...

We applaud Lilly's decision to offer Zepbound® in a more affordable vial format to cash-pay patients, which aligns with ...

The market for anti-obesity drugs has been growing for a while, but is finally about to take off with the entry of two global ...

Eli Lilly is broadening its direct-to-consumer approach by partnering with a digital health company, Noom, which is focused ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Lilly launches Mounjaro in India, offering new option to treat obesity and type 2 diabetes: Our Bureau, Bengaluru Thursday, March 20, 2025, 13:30 Hrs [IST] Eli Lilly and Company l ...

The telehealth company is offering Lilly’s branded form of tirzepatide—approved for weight loss—on its site for $1,899 a ...

Mounjaro, a new treatment for Type 2 diabetes and obesity, has been launched in India after CDSCO approval. The drug, ...

Diabetes management and weight-loss drug Mounjaro has been launched in India by makers Eli Lilly, following approval ... diabetes in the country. A 5 mg vial of the once-weekly drug has been ...

New Delhi [India], March 20 (ANI): Global pharmaceutical company Eli Lilly and Company (India ... (CDSCO), Mounjaro is available in single-dose vials, with pricing set at Rs3,500 for a 2.5 ...